复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

已收盘 04-16 16:08:12

20.460

-0.240

-1.16%

最高20.760	最低20.220	成交量339.50万
今开20.700	昨收20.700	日振幅2.61%
总市值544.03亿	流通市值110.68亿	总股本26.59亿
成交额6,921万	换手率0.63%	流通股本5.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":20.46,"timestamp":1776326892003,"preClose":20.7,"halted":0,"volume":3395038,"delay":0,"changeRate":-0.01159420289855065,"floatShares":540971500,"shares":2659000000,"eps":1.4581157423355149,"marketStatus":"已收盘","change":-0.24,"latestTime":"04-16 16:08:12","open":20.7,"high":20.76,"low":20.22,"amount":69205655,"amplitude":0.026087,"askPrice":20.48,"askSize":2500,"bidPrice":20.46,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":1.4581157423355149,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776389400000},"marketStatusCode":5,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":20.7,"dividendRate":0.017107,"openAndCloseTimeList":[[1776303000000,1776312000000],[1776315600000,1776326400000]],"volumeRatio":1.197336,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":26.7,"timestamp":1776322800000,"preClose":26.8,"halted":0,"volume":15825900,"delay":0,"premium":"-33.26"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2627040795","title":"复星医药：控股股东质押6900万股 占总股本的2.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627040795","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627040795?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:11","pubTimestamp":1776244260,"startTime":"0","endTime":"0","summary":"4月15日，复星医药（600196/02196）发布公告，控股股东复星高科技将其持有的6900万股股份办理质押，占其所持股份的7.18%及公司总股本的2.58%；截至2026年4月14日，复星高科技及其一致行动人累计质押股份5.45亿股，占其所持股份的56.34%及公司总股本的20.42%。2025年，复星医药实现收入416.62亿元，归母净利润33.71亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705999693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0187","BK1515","02196","BK0096","BK0196","BK1191","BK0012","BK0183","600196","BK0239","BK0175","BK1593","BK0028","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627045478","title":"诺和诺德与OpenAI达成战略合作；再生元牵手Telix","url":"https://stock-news.laohu8.com/highlight/detail?id=2627045478","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627045478?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:01","pubTimestamp":1776211308,"startTime":"0","endTime":"0","summary":"政策动向国家医疗保障局持续开展定点医药机构违法违规使用医保基金自查自纠工作国家医疗保障局近日在全国范围内组织开展2026年定点医药机构违法违规使用医保基金自查自纠工作。自查自纠聚焦重点领域“逐渐细化、持续深化”。在既往心血管内科、骨科、血液净化、康复、医学影像、临床检验、肿瘤、麻醉、重症医学等9个重点领域的基础上，本年度进一步将口腔、内分泌、精神医学3个领域纳入自查自纠范围。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705224747.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705224747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0154236417.USD","NVO","BK4588","300558","IE00BKVL7J92.USD","NVOH","IE00BZ1G4Q59.USD","600513","603087","688177","BK4007","BK4599","LU1093756325.SGD","02196","BK4532","LU1093756168.USD","NVOX","301087","002437","600196","BK4585","REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627419777","title":"复星医药(600196.SH)：HLX05-N(即重组抗EGFR人鼠嵌合单克隆抗体注射液)开展Ⅰ期临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2627419777","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627419777?lang=zh_cn&edition=full","pubTime":"2026-04-14 17:05","pubTimestamp":1776157559,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司收到国家药品监督管理局关于同意HLX05-N用于转移性结直肠癌治疗开展Ⅰ期临床试验的批准。复宏汉霖拟于条件具备后就该药品开展相关临床研究。HLX05-N系集团自主研发的西妥昔单抗注射液生物类似药，拟用于转移性结直肠癌及头颈部鳞状细胞癌治疗。根据IQVIA MIDASTM最新数据，2025年，西妥昔单抗注射液于全球范围的销售额约为16.58亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","600196","BK0028","BK0188","BK0187","BK0196","BK0096","BK0239","BK1515","BK1593","BK0183","BK0175","02196","BK1191","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627419136","title":"复星医药：控股子公司FKC289注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2627419136","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627419136?lang=zh_cn&edition=full","pubTime":"2026-04-14 16:56","pubTimestamp":1776156976,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月14日，复星医药(600196.SH)公告称，公司控股子公司复星凯瑞收到国家药监局关于同意FKC289注射液开展I/II期临床试验的批准。该药品为靶向BCMA和CD19的基因修饰CAR-T细胞产品，拟用于复发/难治原发性轻链淀粉样变及复发/难治膜性肾病的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704439910.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704439910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600196","BK0188","BK0183","BK0196","BK0096","BK0012","BK1593","BK0239","BK0187","BK0060","BK1191","BK1515","BK0175","BK0028","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627107719","title":"港股公告掘金 | 胜宏科技今日起招股，引入CPE Rosewood、Janchor Fund等基石投资者","url":"https://stock-news.laohu8.com/highlight/detail?id=2627107719","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627107719?lang=zh_cn&edition=full","pubTime":"2026-04-13 09:22","pubTimestamp":1776043379,"startTime":"0","endTime":"0","summary":"【重大事项】胜宏科技(02476)拟全球发售8334.8万股H股，引入CPE Rosewood、Janchor Fund等基石投资者复星医药(02196)：氟比洛芬酯注射液获注册批准复宏汉霖(02696)：帕妥珠曲妥珠单抗注射液(皮下注射)生物类似药HLX319 的1期临床研究于中国境内完成首例受试者给药高视医疗(02407)：高视创新获得角膜共聚焦显微镜CE注册证书荣昌生物(09995)：维迪西","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","SGXZ81163826.USD","LU0256331488.USD","BK0197","BK4588","02196","CPE","BK1151","09857","06960","01519","BK1515","VXUS","BK4585","BK0214","LU1808992512.USD","BK1128","300476","BK1593","LU1934453819.USD","BK1116","IPOS","LU1979443071.USD","LU0469268626.HKD","BK4213","SGXZ49509284.SGD","02476"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626748195","title":"复星医药(02196)：氟比洛芬酯注射液获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626748195","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626748195?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:40","pubTimestamp":1775814021,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，近日，公司控股子公司重庆药友制药有限责任公司就氟比洛芬酯注射液的药品注册申请获国家药品监督管理局批准，本次获批适应症为用于术后及癌症的镇痛。该药品为集团自主研发的化学药品。截至2026年3月，集团现阶段针对该药品的累计研发投入约为人民币0.34亿元(未经审计)。根据IQVIA CHPA最新数据，2025年，氟比洛芬酯注射液于中国境内(不包括港澳台地区)的销售额约为人民币11.58亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","600196","02196","BK0060","BK0196","BK1515","BK1593","BK0012","BK0096","BK0183","BK0239","BK0187","BK0175","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130162660","title":"复星医药子公司氟比洛芬酯注射液药品注册申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1130162660","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130162660?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:39","pubTimestamp":1775813955,"startTime":"0","endTime":"0","summary":"复星医药宣布，其子公司提交的氟比洛芬酯注射液药品注册申请已获得国家药品监督管理局（NMPA）正式批准。\n此次获批标志着该药物在中国市场的商业化进程取得重要进展，有望为患者提供新的治疗选择。氟比洛芬酯注射液作为一种非甾体抗炎药，主要用于术后镇痛及炎症控制。\n公司表示将积极推进后续生产及市场推广工作，严格遵循监管要求，确保药品质量与用药安全。这一进展也体现了复星医药在创新药研发领域的持续投入与成果转化能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","BK1191","BK1593","BK0175","BK0239","BK1515","02196","BK0060","BK0187","BK0183","BK0028","BK0096","BK0012","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626518842","title":"复星医药最新公告：控股子公司获药品补充申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626518842","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626518842?lang=zh_cn&edition=full","pubTime":"2026-04-09 17:29","pubTimestamp":1775726995,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司控股子公司复宏汉霖自主研发的汉利康(利妥昔单抗注射液)新增适应症的补充申请获国家药监局批准。本次新增适应症包括：联合维泊妥珠单抗等药物治疗既往未经治疗的弥漫大B细胞淋巴瘤(DLBCL)成人患者；联合苯达莫司汀和维泊妥珠单抗治疗不适合接受造血干细胞移植的复发或难治性DLBCL成人患者。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900027730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0060","02196","BK0239","BK1515","BK1593","BK0012","BK0196","BK0096","600196","BK0028","BK0183","BK0188","BK0187","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625793286","title":"复星医药年营收417亿：境内收入同比降4% 陈战宇卸任CFO职务","url":"https://stock-news.laohu8.com/highlight/detail?id=2625793286","media":"雷递网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625793286?lang=zh_cn&edition=full","pubTime":"2026-04-06 19:49","pubTimestamp":1775476195,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司（公司代码：600196 公司简称：复星医药）日前发布截至2025年12月31日的财报。财报显示，复星医药2025年营收为416.62亿元，较上年同期的410.67亿元增长1.45%。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260406/6391110177877379919843687.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260406/6391110177877379919843687.jpeg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33209/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["02196","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624506716","title":"复星医药：董事会审议通过《关于聘任高级管理人员的议案》","url":"https://stock-news.laohu8.com/highlight/detail?id=2624506716","media":"证券日报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624506716?lang=zh_cn&edition=full","pubTime":"2026-04-02 19:59","pubTimestamp":1775131140,"startTime":"0","endTime":"0","summary":"证券日报网讯4月2日，复星医药发布公告称，公司第十届董事会第二十七次会议（临时会议）审议通过《关于聘任高级管理人员的议案》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023693660329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0096","BK0012","BK1191","BK1515","BK0175","BK1593","600196","BK0183","BK0196","BK0028","BK0239","02196","BK0188","BK0187","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193076765","title":"复星医药2026年3月股份变动月报表，无新增发行或回购","url":"https://stock-news.laohu8.com/highlight/detail?id=1193076765","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193076765?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:02","pubTimestamp":1775120561,"startTime":"0","endTime":"0","summary":"上海复星医药(集团)股份有限公司于2026年4月2日披露2026年3月股份变动月报表。公告显示，报告期内公司未发生新增发行、回购或注销股份，各类股本数量与上月保持一致。根据公告，截至2026年3月底，公司H股注册股本为551,940,500股，当月无增减变动；A股注册股本为2,118,488,825股，亦无增减变动。在期权及激励计划方面，公告披露的2025年A股期权计划和2025年H股受限制股份单位计划本期内无期权行使或因行使导致的新股发行，也无库藏股转让。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9589a36a1b64e7c7d7a94166c3b09e9b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624742065","title":"复星医药最新公告：首席财务官变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2624742065","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624742065?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:01","pubTimestamp":1775120496,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司近日收到陈战宇的辞职函，因工作安排调整，其辞去首席财务官职务，自2026年4月2日生效，辞任后仍担任高级副总裁。同日，董事会同意聘任黄智为公司高级副总裁、首席财务官。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200028265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","BK1191","BK1593","BK0175","BK0239","BK1515","02196","BK0060","BK0187","BK0183","BK0028","BK0096","BK0012","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624599418","title":"4月1日复星医药现327.6万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2624599418","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624599418?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:21","pubTimestamp":1775035285,"startTime":"0","endTime":"0","summary":"证券之星消息，4月1日复星医药发生大宗交易，交易数据如下：大宗交易成交价格25.2元，相对当日收盘价折价6.91%，成交13万股，成交金额327.6万元，买方营业部为民生证券股份有限公司北京第一分公司，卖方营业部为中泰证券股份有限公司杭州湖墅南路证券营业部。近三个月该股共发生3笔大宗交易，合计成交9871.0手，折价成交1笔。截至2026年4月1日收盘，复星医药报收于27.07元，上涨1.65%，换手率1.36%，成交量28.84万手，成交额7.77亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100031698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0183","BK1515","BK0188","02196","BK0239","BK0096","600196","BK0196","BK1593","BK0175","BK0187","BK0012","BK0028","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624669596","title":"复星医药(600196.SH)控股子公司药品HLX319获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2624669596","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624669596?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:56","pubTimestamp":1775033772,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司收到国家药品监督管理局关于同意HLX319用于HER2阳性早期或局晚期乳腺癌新辅助治疗开展Ⅰ期临床试验的批准。复宏汉霖拟于条件具备后于中国境内开展该药品的相关临床研究。截至2026年2月，集团现阶段针对HLX319的累计研发投入约为人民币3,387万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","BK0175","BK0096","BK1515","02196","600196","BK0239","BK0188","BK0060","BK0028","BK0196","BK0183","BK0012","BK0187","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623830096","title":"复星医药：重组人透明质酸酶注射液获批临床 累计投入2673万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623830096","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623830096?lang=zh_cn&edition=full","pubTime":"2026-03-31 17:52","pubTimestamp":1774950720,"startTime":"0","endTime":"0","summary":"3月31日，复星医药（600196/02196）发布公告，控股子公司复宏汉霖收到国家药品监督管理局同意开展HLXTE-HAase02（重组人透明质酸酶注射液）Ⅰ期临床试验的批准。该药品旨在促进皮下注射或皮下输注药物的扩散和吸收，计划于条件具备后在中国境内开展相关临床研究。截至2026年2月，集团针对HLXTE-HAase02的累计研发投入约为2673万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690543616.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600196","BK0175","BK1515","BK1593","02196","BK0183","BK0060","BK0187","BK0096","BK1191","BK0196","BK0239","BK0028","BK0188","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623530018","title":"复星医药子公司FXB0871获批临床试验 用于局部晚期或转移性实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2623530018","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623530018?lang=zh_cn&edition=full","pubTime":"2026-03-31 17:52","pubTimestamp":1774950720,"startTime":"0","endTime":"0","summary":"3月31日，复星医药（600196/02196）发布公告，控股子公司药品获得临床试验批准。公司控股子公司复星医药产业近日收到国家药品监督管理局的批准，允许其开展FXB0871用于局部晚期或转移性实体瘤的I期临床研究。该药物是公司与Teva合作开发的PD-1靶向型IL-2融合蛋白，具有增强T细胞活性及降低全身毒性的特点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690544196.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600196","BK0060","BK1191","BK1515","02196","BK0028","BK0012","BK0183","BK0187","BK0196","BK0239","BK0096","BK0175","BK1593","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623373124","title":"【券商聚焦】中信证券：基本医保基金收支和结余整体保持稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2623373124","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623373124?lang=zh_cn&edition=full","pubTime":"2026-03-31 08:59","pubTimestamp":1774918794,"startTime":"0","endTime":"0","summary":"2026年2月医保支出同比增速回升，收支剪刀差有所收窄。该机构预计在医保基金监管力度持续加大，DRG/DIP精细化管理的推动下，2026年全年基金结余率或将延续此前节奏略有提升。医疗健康产业政策改革进入密集期，建议持续关注政策驱动下的医疗健康产业投资机会。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1564","IE00B543WZ88.USD","03933","HK0000165453.HKD","BK1100","IE00BPRC5H50.USD","BK1161","LU0307460666.USD","LU0634319403.HKD","LU1255011170.USD","LU2399975544.HKD","BK1147","09926","09688","LU0405327494.USD","LU2148510915.USD","LU2476274308.USD","LU1719994722.HKD","BK1588","02196","01789","BK0276","BK1593","LU1770034418.SGD","06160","02228","BK0012","LU1969619763.USD","LU0405327148.USD","600030","LU0348735423.USD","LU2488822045.USD","01530","06821","02367","BK1191","06030","LU1997245177.USD","BK1617","LU0348783233.USD","BK1583","LU2495084118.USD","LU1303224171.USD","01099","LU1115378108.SGD","LU1328615791.USD","BK1515","LU0348766576.USD","BK0028","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623870923","title":"每周股票复盘：复星医药（600196）2025年归母净利润增21.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623870923","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623870923?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:44","pubTimestamp":1774719849,"startTime":"0","endTime":"0","summary":"本周关注点来自业绩披露要点：复星医药2025年归母净利润33.71亿元，同比上升21.69%。公司公告汇总复星医药2025年实现营业收入416.62亿元，同比增长1.45%；归属于上市公司股东的净利润33.71亿元，同比增长21.69%；扣除非经常性损益的净利润23.40亿元，同比增长1.12%。上海复星医药（集团）股份有限公司对上海复星高科技集团财务有限公司截至2025年12月31日的经营资质、业务和风险状况进行了评估。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622000486","title":"复星医药（600196）2025年年报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622000486?lang=zh_cn&edition=full","pubTime":"2026-03-26 06:02","pubTimestamp":1774476154,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期复星医药发布2025年年报。截至本报告期末，公司营业总收入416.62亿元，同比上升1.45%，归母净利润33.71亿元，同比上升21.69%。按单季度数据看，第四季度营业总收入122.68亿元，同比上升20.81%，第四季度归母净利润8.47亿元，同比上升11.59%。本报告期复星医药盈利能力上升，毛利率同比增幅4.38%，净利率同比增幅19.21%。该数据高于大多数分析师的预期，此前分析师普遍预期2025年净利润为盈利33.58亿元左右。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600006043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152396741","title":"异动解读 | 复星医药盘中大涨5.21%，2025年净利润增长21.69%并派息提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1152396741","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152396741?lang=zh_cn&edition=full","pubTime":"2026-03-25 09:46","pubTimestamp":1774403208,"startTime":"0","endTime":"0","summary":"复星医药今日盘中大幅上涨5.21%，引起了市场的广泛关注。消息面上，公司于前一日晚间及今日早间陆续发布了2025年年度报告。报告显示，2025年公司实现归属于上市公司股东的净利润33.71亿元人民币，同比增长21.69%；基本每股收益1.27元，同比增长22.12%。此外，根据年报披露，公司创新药品收入在2025年达到98.93亿元，同比增长29.59%，成为业绩增长的重要引擎。全年研发总投入59.13亿元，其中创新药相关研发投入持续增长。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":0.0258},{"period":"1month","weight":0.0781},{"period":"3month","weight":-0.0282},{"period":"6month","weight":-0.1288},{"period":"1year","weight":0.4799},{"period":"ytd","weight":0.0588}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.0044},{"period":"3month","weight":-0.0363},{"period":"6month","weight":0.0277},{"period":"1year","weight":0.2087},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044492},{"month":2,"riseRate":0.714286,"avgChangeRate":0.036178},{"month":3,"riseRate":0.571429,"avgChangeRate":0.044258},{"month":4,"riseRate":0.428571,"avgChangeRate":0.031735},{"month":5,"riseRate":0.461538,"avgChangeRate":0.035265},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.026545},{"month":7,"riseRate":0.615385,"avgChangeRate":0.027595},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.041651},{"month":9,"riseRate":0.461538,"avgChangeRate":0.011609},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020359},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034495},{"month":12,"riseRate":0.428571,"avgChangeRate":0.015123}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}